Page 796«..1020..795796797798..810820..»

Newsmakers 2020: Ryan Pourjam and the tragedy that devastated Ottawa’s Iranian community – Ottawa Citizen

Posted: December 26, 2020 at 6:53 am

Below, one of our 10 newsmakers: Ryan Pourjam

With just 265 words, 13-year-old Ryan Pourjam laid bare the human tragedy of the downing of Ukraine International Airlines flight PS752.

In a grey sweater and blue jeans, Ryan stood before a gathering of more than 200 mourners at Carleton University in the memory of his dad, Mansour Pourjam, one of 176 people who died in the crash, just the week before.

It happened at a time when the world was on edge. Iran was on high alert after having launched a missile attack on American bases in Iraq in retaliation for a U.S. drone strike on Jan. 3 that had killed prominent Iranian general Qasem Soleimani. In the tense hours that followed, Irans Revolutionary Guard mistook the Boeing 737, which had taken off from Tehran airport just minutes before, for an incoming American cruise missile. It launched two surface-to air-missiles at the defenceless airliner.

The innocents aboard Flight PS752 were collateral damage in the realpolitik of Mideast conflict.

Mansour was one of 57 Canadians, eight of them from Ottawa, who lost their lives in the Jan. 8 crash.

Also killed were Alireza Pey, CEO and founder of Kanata-based MessageHopper; Roja Azadian, who was travelling alone after her husband learned at Tehran airport that his ticket had been cancelled; architect Fereshteh Maleki Dizaje, whowas returning from celebrating her daughters wedding in Tehran; and Fareed Arasteh, a Carleton University PhD student in molecular genetics who had been married in Tehran only days before. A trio of uOttawa students were also aboard the doomed flight:Alma Oladi, a PhD student in mathematics with a specialty in genomics statistics; Saeed Kashani, a PhD student in chemistry; and Mehraban Badiei, a first-year student in health sciences.

Original post:
Newsmakers 2020: Ryan Pourjam and the tragedy that devastated Ottawa's Iranian community - Ottawa Citizen

Posted in Molecular Genetics | Comments Off on Newsmakers 2020: Ryan Pourjam and the tragedy that devastated Ottawa’s Iranian community – Ottawa Citizen

Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies to Market immunoSEQ Assay, the Leading Quantitative…

Posted: December 26, 2020 at 6:53 am

MORRISVILLE, N.C.--(BUSINESS WIRE)--Q2 Solutions, a leading global clinical trial laboratory services organization, resulting from an IQVIA and Quest Diagnostics joint venture, today announced a partnership with Adaptive Biotechnologies, a pioneer and leader in immune-driven medicine. Q2 Solutions will offer its customers the immunoSEQ Assay, Adaptives next-generation sequencing (NGS) based immunosequencing solution, which is used to quantify adaptive immune receptors at high-throughput, leveraging the companys new immunosequencing kit. Q2 Solutions will also offer immunoSEQ T-MAP COVID, a proprietary research product and data analysis service to accurately and reproducibly assess the T cell immune response to COVID-19 vaccines in development and track the persistence of that response over time. The specific terms of the partnership are confidential.

We are delighted to be the first large global laboratory services organization to enter into a partnership with Adaptive Biotechnologies to provide clinical trial services with both immunoSEQ and immunoSEQ T-MAP COVID, the first molecular T cell monitoring tool for SARS-CoV-2, said Kellie Yarnell, VP, Genomic Laboratories, Q2 Solutions. These new genomics services will further expand our global Immuno-Oncology and COVID-19 comprehensive testing portfolio solutions offered to our pharma clients, emphasized Dr. Patrice Hugo, Chief Scientific Officer at Q2 Solutions.

The immunoSEQ Assay allows pharmaceutical companies to understand adaptive immune responses, which adds valuable insight throughout the drug development lifecycle including efficacy, dosing, optimal drug combinations, mechanisms of action, safety and adverse event monitoring. It also provides drug developers with a way to identify key biomarkers of drug response and/or diagnostic targets. The technology enables accurate and quantitative assessment of the T cell characteristics and dynamics, including the unparalleled power to understand immune responses to COVID-19 in never-before-possible ways through the immunoSEQ T-MAP COVID platform.

We are excited to partner with Q2 Solutions, one of the worlds premier clinical R&D service providers, to offer immunoSEQ and immunoSEQ T-MAP COVID to their pharmaceutical customers, said Julie Rubinstein, President, Adaptive Biotechnologies. By translating the genetics of the adaptive immune system at massive scale with a clinically robust assay, Q2 Solutions can help advance their customers clinical programs to address SARS-CoV-2, as well as in immune-mediated disease areas.

Q2 Solutions will run studies directly for its pharma and biotech clients, utilizing both blood and tumor tissue sample matrices. Q2 Solutions will use Adaptives proprietary bioinformatics pipeline to perform analytical testing and data analysis before releasing to pharma customers. For more information on immunoSEQ, visit http://www.immunoseq.com.

About Q2 Solutions

Q2 Solutions is a leading global clinical trial laboratory services organization providing comprehensive testing, project management, supply chain, biorepository, biospecimen and consent tracking solutions. Leveraging our next generation technologies, we deliver agile and precise services designed to meet the diverse needs of our clients. We provide scientific expertise and innovative solutions for ADME, bioanalytical, genomics, vaccines and central laboratory services, including flow cytometry, anatomic pathology, immunoassay, molecular and companion diagnostics, with meticulous regional and global clinical trial implementation support and high-quality data delivery. At Q2 Solutions, our work is rooted in research, grounded in collaboration, and guided by our passion to turn the hope of patients and caregivers around the world into the help they need. To learn more, visit http://www.q2labsolutions.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is natures most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com and follow us on http://www.twitter.com/adaptivebiotech.

Continue reading here:
Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies to Market immunoSEQ Assay, the Leading Quantitative...

Posted in Molecular Genetics | Comments Off on Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies to Market immunoSEQ Assay, the Leading Quantitative…

Flavors added to vaping devices damage the heart, vanilla custard the most toxic of all – Study Finds

Posted: December 23, 2020 at 11:58 am

TAMPA, Fla. While health officials and lawmakers continue trying to steer young people away from vaping, the wide variety of enticing flavors added to these products make that a tough task. Although most of the worry over vaping comes from the risk of addiction, lung damage, and threat of switching to conventional cigarettes, a new study finds the flavoring chemicals these products use may be just as harmful as anything else. Researchers from the University of South Florida Health say vaporized flavoring molecules are toxic to the heart and damage the organs ability to beat correctly.

While other studies find that vaping is generally less harmful than smoking traditional tobacco products, the nicotine and other chemicals in e-cigarettes still damages the heart and lungs. Until now however, researchers say the impact of flavoring additives inhaled into the bloodstream remained unclear.

The flavored electronic nicotine delivery systems widely popular among teens and young adults are not harm-free, says principal investigator Dr. Sami Noujaim in a university release. Altogether, our findings in the cells and mice indicate that vaping does interfere with the normal functioning of the heart and can potentially lead to cardiac rhythm disturbances.

Dr. Noujaims study is one of the first to investigate the cardiotoxic effects of flavoring chemicals added to the e-liquids in electronic nicotine delivery systems (ENDS). ENDS include a variety of different vaping products like vape pens, mods, and pods.

Researchers define vaping as inhaling aerosols (tiny droplets) which e-cigarettes create by heating liquid nicotine and solvents like propylene glycol and vegetable glycerin. A vaping devices battery-powered heater converts this liquid into a smoke-like mix, or vapor.

The study tested how three popular e-liquid flavors fruit, cinnamon, and vanilla custard affect cardiac muscle cells (HL-1) of mice. After being exposed to e-vapor in a lab dish, the results reveal all three flavors are toxic to HL-1 cells.

The USF team also examined what happens to cardiac cells grown from human stem cells that are exposed to three types of e-vapors. The first substance containing only solvents interfered with the cells electrical activity and beating rate. The second substance, containing both nicotine and solvents, proved to be even more toxic to the heart cells.

The third substance however, containing nicotine, solvents, and vanilla custard flavoring, caused the most damage to the heart and its ability to spontaneously beat correctly. Researchers also determined that vanilla custard flavoring is the most toxic of the varieties tested.

This experiment told us that the flavoring chemicals added to vaping devices can increase harm beyond what the nicotine alone can do, Dr. Noujaim says.

The study also tested flavored vapings impact on live mice. Researchers implanted each subject with a tiny electrocardiogram device before exposing them to 60 puffs of vanilla-flavored e-vapor five days a week for 10 weeks.

Study authors looked at how this exposure impacted heart rate variability (HRV), which is the change in time intervals between successive heartbeats. The results show that HRV decreased in vaping mice compared to those only exposed to puffs of clean air.

The USF team finds vaping interferes with normal HRV by disrupting the autonomic nervous system and its control over heart rate. Mice exposed to flavored vaping are also more prone to a dangerous heart rhythm problem called ventricular tachycardia.

Researchers say they still have to confirm these results in humans. Dr. Noujaim urges policymakers to continue looking at the growing evidence that vaping is not a particularly safer alternative to smoking.

Our research matters because regulation of the vaping industry is a work in progress, Dr. Noujaim explains. The FDA needs input from the scientific community about all the possible risks of vaping in order to effectively regulate electronic nicotine delivery systems and protect the publics health. At USF Health, in particular, we will continue to examine how vaping may adversely affect cardiac health.

The study appears in the American Journal of Physiology- Heart and Circulatory Physiology.

Read more from the original source:
Flavors added to vaping devices damage the heart, vanilla custard the most toxic of all - Study Finds

Posted in Florida Stem Cells | Comments Off on Flavors added to vaping devices damage the heart, vanilla custard the most toxic of all – Study Finds

Jim McMahon broke his neck playing for Vikings, and found out about it 17 years later – TwinCities.com-Pioneer Press

Posted: December 23, 2020 at 11:56 am

In 2010, Jim McMahon was getting results from what he thought was a routine examination for workers compensation. The doctor asked him, When did you break your neck?

Suddenly, the former quarterbacks mind shot back to when he played one season for the Vikings in 1993. In a 17-10 playoff loss to the Giants in New York on Jan. 9, 1994, McMahon was battered and knocked out of the game twice but returned each time.

I said, I have a pretty good idea, McMahon said in a phone interview.

On the second play of the third quarter, with the Vikings leading 10-3, McMahon was sandwiched by defensive linemen Mike Fox and Keith Hamilton, the latter belting him in the head. McMahon was down on the field for nearly two minutes, and CBS play-by-play announcer Pat Summerall later said on the air he had been diagnosed with a mild concussion.

I believe thats the game that I broke my neck, McMahon said. I remember lying on the field for quite a while. I had all my senses but I was like, Dont touch me. I cant feel my legs.

McMahon eventually was able to get up and slowly walked off the field. He was replaced by Sean Salisbury but returned on Minnesotas next series.

I remember rolling out to throw a pass and (Fox) jumped up to block the pass, McMahon said of a play late in the third quarter. He brushed against my helmet, and then my legs went numb again.

McMahon was down again for more than a minute, and again was replaced by Salisbury. But McMahon returned with five minutes left in the game after CBS analyst John Madden had said on the air he should sit out the rest of the afternoon.

McMahon went on to play three more NFL seasons.

After that game, you go back to Minnesota and you see the coach (Dennis Green), and he says, Have a good summer, and then you leave, McMahon said. I guess they never caught (the neck injury) with any X-rays the next three years because I passed every physical. They told me (in 2010) that the C6 and C7 vertebrae were cracked and compressed, which means they were squished together and cracked at the ends.

McMahon was beaten up plenty while playing in the NFL from 1982-96, suffering other neck injuries, numerous concussions and shoulder injuries. He had 12 knee surgeries and suffering bruised ribs and a lacerated kidney. In 2012, McMahon, who now lives in Scottsdale, Ariz., was diagnosed as being in the early stages of dementia but said he has felt better in recent years.

McMahon, 61, goes to a chiropractor in New York every three months to have his neck aligned to help the flow of spinal fluid. And last December he went to Columbia University Irving Medical Center in New York to have 275 million stem cells added into both shoulders, both elbows, both knees, and his neck, spine and brain.

McMahon helped lead the Chicago Bears to a 15-1 record in 1985, and a resounding 46-10 win over New England in Super Bowl XX. Had he not been sidelined by injuries in three Chicago seasons after that, the Bears might have won another Super Bowl or two.

McMahon doesnt watch the NFL much now. The Bears will face the Vikings on Sunday at U.S. Bank Stadium, and McMahon isnt expected to watch. But he likely will check out the score.

Even though he played just one season with the Vikings and it didnt end well, McMahon has fond memories of Minnesota. He has returned to the Twin Cities twice in the past two years for autograph shows and to play golf.

I enjoy Minnesota, he said. I like to go up there and see some old teammates and have a beer and have some laughs.

McMahons latest visit was in September, when he stayed at the Blaine home of Buddy Becker, a friend and real-estate agent. Becker is friends with Tommy Kramer, a Vikings quarterback from 1977-89 who has been living at his home. Former NFL quarterback Jim McMahon, right, who played with the Minnesota Vikings in 1993, visits with Tommy Kramer, a Vikings quarterback from 1977-89, at an autograph signing at Route 47 Pub & Grub in Fridley in September 2020. (Courtesy of Buddy Becker)

McMahon and Kramer got to know each other a bit when their teams faced each other twice a season in the old NFC Central Division. A few years ago, they started tweeting at one another, and since have become much closer.

Theyre golf, drinking and singing buddies, Becker said. When Jim was here in September, I have a video of him and Tommy singing the Waylon Jennings song, Good Hearted Woman. They were singing to their exes.

McMahon and Kramer faced off in what was perhaps the most memorable regular-season game of McMahons career. Entering the Sept. 19, 1985, game at the Metrodome, the Bears and the Vikings were both 2-0.

The game was played on a Thursday night and televised nationally by ABC with its Monday Night Football broadcasting team of Frank Gifford, Joe Namath and O.J. Simpson. McMahon had been in the hospital for two days during the week with a pinched nerve in his neck and head coach Mike Ditka had announced that Steve Fuller would start at quarterback.

I had been in the hospital in Chicago in traction, and Ditka told me I wasnt going to play, McMahon said. The night before the game, I was sitting in my (Twin Cities hotel) room icing my shoulder, my back and my neck. Then one of the coaches comes up and says, Ditkas ticked off. Why arent you at (a team) meeting? So, I had to go down and listen to Ditka rant and rave about me, and I said, Why do I have to be here? You told me Im not playing.

McMahon said he was given painkillers before the game, and that once the game got underway, he started bugging Ditka the whole first half that you better let me play.

With the Bears trailing 17-9 midway through the third quarter and Fuller ineffective, Ditka finally inserted McMahon. The quarterback joked that he probably did so because Ditka was tired of being pestered on the sideline.

On the first play, a screen pass was called, McMahon said. I was a little wobbly when I dropped back because of all the painkillers I had taken. But I saw a blitz, and downfield Willie Gault was 10 yards past his man, so I threw it to him instead.

The speedy wide receiver scored on a 70-yard reception to cut the deficit to 17-16. But Ditka wasnt happy.

When I came off the field, he grabbed me and said, What play did you call? Why did you throw it to (Gault)? I said, Because he was open.

On Minnesotas next possession, Kramer threw an interception. On the next play, McMahon tossed a 25-yard touchdown pass to Dennis McKinnon for a 23-17 Bears lead.

Later in the third quarter, McMahon threw a 43-yard touchdown pass to McKinnon for a 30-17 lead. That made it three TD passes in a span of 6 minutes, 40 seconds, and the Bears were on their way to a 33-24 win.

We should have won that game, Kramer said. McMahon hadnt even been on the field and then comes in and nobodys guarding Willie Gault. Willie Teal was supposed to be on him.

The win helped springboard the Bears to a 12-0 start before they lost their only game of the season, 38-24 at Miami. McMahon completed 8 of 15 passes for 236 yards.

It was a fun third quarter, McMahon said. It was awesome. People got to see that we were more than just a defensive football team.

Between 1985-88, McMahon was 29-3 as Chicagos starting quarterback but missed about as many games as he played. So, the Bears traded him to San Diego, where he played one forgettable season.

McMahon then went to Philadelphia to serve as Randall Cunninghams backup from 1990-92 but had 12 starts. Then it was on to Minnesota in 1993. There, he started a career-most 12 games and went 8-4. He missed four games due to a dislocated shoulder, and the Vikings finished 9-7. Minnesota Vikings quarterback Jim McMahon reacts after a third-down pass intended for Quadry Ismail falls incomplete, forcing Minnesota to punt in an NFL football game against the Green Bay Packers at the Metrodome in Minneapolis on Sept. 26, 1993. Vikings placekicker Fuad Reveiz kicked a 22-yard field goal his fifth of the game with four seconds left to lift Minnesota to a 15-13 victory. (Jean Pieri / Pioneer Press)

We had a pretty good defense, and offensively we had some weapons in Cris Carter and Anthony Carter, McMahon said. My biggest memory that season was beating the Packers twice and the Bears twice.

The Vikings beat the Bears 10-7 at the Metrodome in Week 2 and 19-12 in Week 8 on Monday Night Football at Chicago. It marked the only times in McMahons career he defeated the Bears as a starter.

It was nice to play back home, McMahon said of the win at Soldier Field. They gave me a nice ovation. The fans always treated me well in Chicago. But the sweetest revenge was getting a victory.

During his 1982-88 Chicago tenure, McMahon had the image of being a punk rocker, which he attributed to one bad haircut. He said he didnt write any lyrics for The Super Bowl Shuffle video in which he sang, Im the punky QB known as McMahon. And he said the sunglasses he regularly wore were for medical reasons.

McMahon said his image with the Bears was a media creation, and Minnesota teammates never saw it.

He had that image of wearing sunglasses and the headband and all those kind of things, but he was just a normal guy, said Brad Johnson, Minnesotas third-string quarterback in 1993. Wed go over to his house and play darts and cards. I remember him as just a really good guy, a good teammate.

That season marked the only time McMahon led a team other than Chicago to the playoffs. He completed 60.4 percent of his passes, a career best as a starter, and threw for 1,968 yards with nine touchdowns and eight interceptions.

He was tough, like a Scott Studwell playing quarterback, said former Vikings cornerback Carl Lee, referring to the rugged former linebacker. He got beaten up a lot, but he never wanted to miss a play.

That attitude was on display to start the playoffs at Giants Stadium, when the temperature was 20 degrees with a 21-mph wind that made the wind-chill factor 4 degrees. Going against a rugged defense that featured legendary linebacker Lawrence Taylor, McMahon completed 12 of 25 passes for 145 yards and a touchdown.

He got knocked around a lot in that game, but I didnt know he broke his neck, said Roger Craig, then a Vikings running back. Thats crazy. Thats wild. He was a tough, tough guy, and he was great leader. If I broke my neck, man, that would have made me retire right away.

Of course, McMahon didnt know it then and played three more seasons.

After the Vikings opted to bring in quarterback Warren Moon in 1994, McMahon spent that year as backup in Arizona. He then moved on to Green Bay to serve as Brett Favres backup in 1995 and 1996. In his final NFL game, he watched from the sidelines as the Packers beat New England 35-21 in Super Bowl XXXI, earning McMahon a second championship ring.

McMahon still keeps up with Favre. He reached out to him when he saw that Beckers home has a urinal in a basement bathroom with a Packers logo at the bottom of the bowl.

Jim got a kick out of it, and the first thing he did was send a picture of it to Brett Favre, and Brett sent a text back laughing, Becker said. Former NFL quarterback Jim McMahon, who played with the Minnesota Vikings in 1993, on the beach in Cabo, Mexico on Dec. 17, 2020. (Courtesy of Jim McMahon)

McMahon spends much of his time now at his Arizona home, and recently bought a house in Mexico. He said he still at times gets bad headaches because the spinal fluid is acting up and must go into a dark room for relief. But hes been able to keep that mostly under control by going regularly to Rock Hill, N.Y., to have adjustments made by chiropractor Scott Rosa.

McMahon said he also has been helped by the visit to a clinic last December in Medellin, Colombia, when the stem cells were added, and by having a medical prescription for marijuana. McMahon said hes looking himself to get into the cannabis business.

My body is actually feeling a heck of a lot better now, he said.

McMahon was battered plenty in the NFL, most famously when Packers defensive end Charles Martin body slammed him to the turf in Week 12 in 1986. That ended his season due to a shoulder injury.

Not as well documented has been the beating he took seven years later with the Vikings in the playoffs. Any regrets?

I went back in, like an idiot, he said.

Visit link:
Jim McMahon broke his neck playing for Vikings, and found out about it 17 years later - TwinCities.com-Pioneer Press

Posted in Arizona Stem Cells | Comments Off on Jim McMahon broke his neck playing for Vikings, and found out about it 17 years later – TwinCities.com-Pioneer Press

Stem Cell Therapy Shows 2-year Benefit for Progressive MS Patients in Phase 1 Trial – Multiple Sclerosis News Today

Posted: December 22, 2020 at 7:59 am

Lesser or stable disability over two years was evident in most progressive multiple sclerosis (MS) patients given a stem cell treatment in a small Phase 1 clinical trial, supporting a larger study now underway, researchers report.

These results suggest that a treatment using mesenchymal stem cell-derived neural progenitors (MSC-NPs) can safely and effectively ease inflammation in progressive MS.

But for a subset of patients, particularly those with more advanced disease and greater disability, this treatment did not sufficiently counter a continued inflammatory response in the brain.

The study, Mesenchymal stem cell-derived neural progenitors in progressive MS: Two-year follow-up of a phase I study, was published in the journal Neurology: Neuroimmunology and Neuroinflammation.

MSC-NPs are seen as a possible way of treatingpeople with progressive MS, who have few effective disease-modifying treatments available. They are essentially stem cells collected from a patients bone marrow that are expanded and matured to produce factors involved in modulating the immune response and innervous tissue growth and survival.

An open-label Phase 1 trial (NCT01933802) investigated this stem cell treatment in 20 adults with stable primary(four PPMS patients) or secondary progressive MS(16 SPMS patients) and significant disability.

All received a total of three injections of MSC-NPs, given directly into the spinal canal three months apart. They were then evaluated at three and six months, and again at two years, after the final treatment to determine its long-term safety and tolerability, and for signs of potential effectiveness.

An initial analysisat six months post-treatment found lesser disability in most trial participants (15 of the 20) andbetter muscle strength in 14 of them. Greater exercise capacity was also seen in four of the 10 patients able to walk at the studys start, and two nonambulatory patients gained an ability to walk using assistive devices.

Researchers now reported clinical findings at two years after treatment. All 20 completed two-year follow-up assessments, buttwo who were severely disabled could not do a final in-person visit. They were examined via telemedicine and did not provide biomarker samples.

Disability was evaluated using the Expanded Disability Status Scale (EDSS), in which a higher score indicates more severe disability. The two who moved to telemedicine had EDSS scores of 8.0.

At six months, eight participants had an EDSS reduction of at least 0.5 points, including four with disability reductions of two or more points. At the two-year follow-up, seven of these eight people continued to show improvements in their EDSS scores, including two who showed a sustained 2.0 or more point reduction.

The eighth patient, whose disability had initially improved by one point, showed a worsening in disability at two years.

Of the 10 patients without initial improvements in EDSS scores, six had no evidence of disease progression throughout the study and follow-up. Two others worsened at each follow-up, and two showed worsening disease between the six-month and two-year examinations.

Of the 10 nonambulatory patients at the trials start, four showed improvements in walking speed greater than 20% at three months post-treatment. At two years, three had maintained these walking speed gains, while one fell just below the 20% improvement mark.

One of the two people unable to walk at the beginning of the study completed the walking test at both the three-month and two-year exams. One other patient, with an initial normal walking speed, maintained that speed throughout the trial and follow-up periods.

These results indicate that multiple MSC-NP treatments led to disability reduction for most progressive patients with long-standing disease. But those who sustained these gains at two years after treatment had lower EDSS and ambulatory status at baseline or the studys start, the researchers wrote.

A subset of patients with initial improvement failed to maintain shown benefits, while others showed no disease progression throughout the follow-up.

Cerebrospinal fluid (CSF) levels of CCL2, a pro-inflammatory factor, were lower following treatment, while levels of the anti-inflammatory TGF beta 2 rose post-treatment, consistent with previous studies of similar treatments.

Interestingly, no difference here was observed between patients whose disability improved in response to the treatment (responders) and those who failed to improve (non-responders).

However, some inflammatory factors were seen to rise after treatment in non-responders, but not among those who responded to treatment. This suggests that a continued inflammatory response may hinder clinical response to MSC-NP use.

Neurofilament light chain (NfL) levels in the CSF, a marker of nerve cell degeneration and damage, can be elevated in MS patients. Among a small number of trial patients with high NfL levels prior to treatment, these levels rose further in nonresponders after treatment while they declined among responders.

We observed that most subjects who received repeated [MSC-NP] injections exhibited either a reversal in disability or lack of disease progression that was sustained for 2 years after treatment, the researchers wrote.

The impact of any efficacy conclusion, however, are severely limited by the very small number of patients in the study and the lack of blinding and placebo controls, they added.

An ongoing and placebo-controlled Phase 2 clinical trial (NCT03355365), which opened last year, is now investigating the safety and efficacy of repeat MSC-NP injections in progressive MS patients. The study is expected to have enrolled50 adults with progressive MS (40 SPMS and 10 PPMS), being given a total of six injections of either MSC-NPs or a placebo every other month for a first year.

In its second year, those in the MSC-NP group cross to the placebo group and those previously on a placebo move to treatment again for six total injections given every two months. This single-site trial at the Tisch MS Research Center of New Yorkwill run for three years, and is expected to finish in late 2023.

Aisha Abdullah received a B.S. in biology from the University of Houston and a Ph.D. in neuroscience from Weill Cornell Medical College, where she studied the role of microRNA in embryonic and early postnatal brain development. Since finishing graduate school, she has worked as a science communicator making science accessible to broad audiences.

Total Posts: 81

Read more:
Stem Cell Therapy Shows 2-year Benefit for Progressive MS Patients in Phase 1 Trial - Multiple Sclerosis News Today

Posted in Stem Cell Treatments | Comments Off on Stem Cell Therapy Shows 2-year Benefit for Progressive MS Patients in Phase 1 Trial – Multiple Sclerosis News Today

Physio Logic Brings Cutting-edge Regenerative Treatments for Sport Injuries and Arthritis to New York City – PRNewswire

Posted: December 22, 2020 at 7:59 am

NEW YORK, Dec. 17, 2020 /PRNewswire/ -- Physio Logic, a leading provider of integrated health services in New York City and surrounding areas, continues to demonstrate its commitment to excellence in the field of Regenerative Medicine and Stem Cell Therapy by entering into a collaboration with Regenexx, a worldwide network of specially trained physicians providing the world's most advanced, research-driven, regenerative medicine and stem cell therapy treatments. The partnership brings cutting-edge regenerative treatments to New York City residents suffering from sports injuries or degenerative diseases.

The Regenerative Medicine division of Physio Logic is led by Dr. Tanuj Palvia, MD, a specialist in regenerative medicine and interventional orthopedics focused on the treatment of musculoskeletal injuries and degenerative orthopedic conditions.

"Stem Cell Therapy is one of the most innovative treatments available today but, being so new, patients need to know they're receiving the best possible care. As a physician, I hold myself and my practice to the highest standards and, being aligned with Regenexx adds that extra assurance patients need to know they're in good hands. Whether it's a nagging sports injury or slow degeneration, you're going to get the highest quality of integrated care right here at Physio Logic," said Dr. Palvia.

Interventional Orthobiologics is a specialty that focuses on using your body's natural healing agents to treat orthopedic injuries with the goal of reducing pain and improving joint function. The variety of orthobiologics available to Regenexx physicians, such as bone marrow stem cells and platelet-rich plasma (PRP), allow them to create a treatment plan to best support your recovery. It can be used in the treatment of conditions such as arthritis and injury to ligaments, tendons, cartilage, or bone.

"Being selected to represent the Regenexx brand in New York City speaks to the quality of our facility, our providers, and the care we give our patients," said Dr. Rudy Gehrman, CEO & Founder of the Brooklyn based clinic. "Physio Logic is raising the standard of healthcare in New York and our partnership with Regenexx is an extension of the quality, integrative care we provide to every patient that walks through our door."

Regenexx physicians are required to have thousands of hours of experience performing precise, injection-based treatments using image guidance for a range of body parts and injuries. Their strict acceptance criteria means that Regenexx only chooses the most qualified physicians to join their network. Physio Logic's Interventional Pain Specialist, Dr. Tanuj Palvia, MD, is ranked among them.

To learn more about Physio Logic and Regenerative Medicine, go to https://physiologicnyc.com/regenerative-medicine/

About Physio LogicPhysio Logic brings together an expert team of open-minded medical doctors, physical therapists, chiropractors, acupuncturists, massage therapists, nutritionists, health coaches, biohackers, and Pilates instructors. Our unique collaborative approach, coupled with our ability to assess patients holistically, is used to create a custom care plan tailored to patients' needs. For more information on Physio Logic, visit https://physiologicnyc.com or call (718) 260-1000.

About RegenexxRegenexx is a nationwide network of physicians who practice Interventional Orthopedics, a new specialty that focuses on using the most advanced regenerative protocols available as an alternative to many orthopedic surgeries. Regenexx has published roughly half of the research worldwide on the use of orthobiologics for treating orthopedic injuries, and our patented treatment lab-processing and treatment protocols allow us to achieve unmatched results. Our procedures use your body's natural healing agents including blood platelets and bone marrow concentrate to repair damaged bone, muscle, cartilage, tendons and ligaments. For more information on Regenexx, visit https://regenexx.com.

Media contact:Alan Sott[emailprotected](718) 260-1000

SOURCE Physio Logic

http://www.physiologicnyc.com

See more here:
Physio Logic Brings Cutting-edge Regenerative Treatments for Sport Injuries and Arthritis to New York City - PRNewswire

Posted in Stem Cell Treatments | Comments Off on Physio Logic Brings Cutting-edge Regenerative Treatments for Sport Injuries and Arthritis to New York City – PRNewswire

New Combination Therapy Tested By Children’s May Offer Hope For Leukemia Patients – WVXU

Posted: December 22, 2020 at 7:59 am

Cancer cells pose an uncanny ability to make new cells and dodge drugs, "somewhat like would-be robbers hacking the bank's alarm code," one doctor explains. But researchers at Cincinnati Children's Hospital Medical Center have figured out how cancer cells rewire themselves and, in turn, how to possibly overcome drug resistance.

This drug resistance may explain why some acute myeloid leukemia (AML) and other cancer patients suffer fatal relapses despite many improvements in leukemia outcomes over the years, according to a Children's news release.

"Overcoming resistance to therapy remains a holy grail of leukemia treatment," says Yi Zheng, Ph.D., director, experimental hematology and cancer biology at Cincinnati Children's. Zheng and his colleagues have now discovered a way to boost the effectiveness ofmTOR inhibitors, which prohibit unwanted cell proliferation.

"While the latest study is based on mouse models, building upon the findingspublished Dec. 21, 2020, in PNASeventually could improve outcomes for people with AML, and possibly other forms of cancer," a release says.

What Happens When Treatments Target mTOR?

"Using a novel mouse model, we have learned that deleting the mTOR gene prompts blood stem cells to multiply rapidly to open other pathways to continue producing new blood cells," says Zheng, the study's senior author. "We also found that leukemia cells use a similar response to continue multiplying despite mTOR-inhibiting treatments."

He says attacking mTOR essentially sets off alarms among hemopoietic stem cells (HSCs), which act like blood cell factories deep in bone marrow. Then the cells themselves produce a flood of new, re-wired blood cells. These re-wired stem cells, treated with mTOR inhibitors, can begin multiplying, rendering mTOR inhibitor drugs useless.

The co-authors say mTOR treatment resistance can be counteracted by inhibiting activity of the MNK, CDK9 or c-Myc genes. So-called BET inhibitors can act against c-Myc activity. Other inhibitors that are in clinical trials can act against CDK9.

Next Steps

Scientists at Cincinnati Childrens have already launched some of the research needed to prepare the combination therapies for in vivo test leading to human clinical trials, the news release says. That process will take time, but since mTOR inhibitors have been widely tested in clinical trials, investigators have a head start on exploring combination therapies.

Longer term, the findings may extend beyond AML, Zheng says, because mTOR has been a recognized target in most human cancers, including solid tumors like brain tumors.

The rest is here:
New Combination Therapy Tested By Children's May Offer Hope For Leukemia Patients - WVXU

Posted in Stem Cell Treatments | Comments Off on New Combination Therapy Tested By Children’s May Offer Hope For Leukemia Patients – WVXU

For Patients With HMA-Resistant MDS, What Are Their Options? – AJMC.com Managed Markets Network

Posted: December 22, 2020 at 7:59 am

Although hypomethylating agents (HMAs) are a cornerstone of treatment for the majority of myelodysplastic syndrome (MDS) cases, there are patients who are resistant to such treatment, representing a need for other treatment options, reports the study in Therapeutic Advances in Hematology.

Both azacitidine (AZA) and decitabine (DEC) are HMAs approved in the United States for all patients with MDS, and most patients who respond to the treatments will do so within the first 6 cycles. With this threshold, its recommended to complete 6 cycles of AZA before considering a patient as HMA refractory.

Since the prognosis of patients failing HMA therapy is dismal except for the small minority of patients eligible for allo-SCT [allogeneic stem cell transplant], there is an urgent need for both prevention of HMA failure by (1) optimization of frontline therapies (eg, adding synergistic agents to HMA therapy) and/or (2) improved salvage therapies for HMA-refractory MDS patients, explained the researchers.

For these patients who are resistant to HMA treatment, there are no formal recommendations, but several options, spanning from novel HMAs to chemotherapy, have been or are currently being studied in the setting.

Outside of AZA and DEC, which have short half-lives potentially limiting their biologic activity, guadecitabine has emerged as a more effective, easier-to-administer option that has also demonstrated tolerability.

Oral ASTX727, a combination of cedazuridine and DEC, has preliminary data from 50 patients with MDS or chronic myelomonocytic leukemia. The data show an overall response rate (ORR) of 62%, and the most common grade >3 adverse events were hematologic (eg, neutropenia, 48%; thrombocytopenia, 38%; anemia, 22%; leukopenia, 20%), febrile neutropenia (38%), and pneumonia (20%). There is currently an ongoing phase 3 trial comparing the oral option with intravenous DEC.

An oral option of AZA, CC-486, is also being tested in clinical trials.

The review, while highlighting promising treatment options for these patients, also offers rationale for not using certain treatment options. For example, although lenalidomide has proven effective in the first-line setting for patients with del(5q), the treatment has a limited benefit in these patients who are refractory to HMAs, leading researchers to recommend against lenalidomide being used outside of the frontline setting for the subgroup of patients.

Chemotherapy, frequently used for medically fit patients as a bridge to allo-SCT, was tested in an international multicenter retrospective analysis of over 300 patients who were refractory to HMA. The study, which used 3 intensive induction chemotherapy regimens, boasted an ORR of 41% and median overall survival of 10.8 months. Forty percent of patients were bridged to allo-SCT, the only potentially curative options for patients with MDS.

Other research has indicated that medically fit should not exclusively qualify patients for chemotherapy treatment, with some data suggesting that the decision should also take into account molecular and cytogenetic features.

Ongoing research is also being targeted at combining HMAs with intensive chemotherapy, other forms of epigenetic therapy, venetoclax, and immune checkpoint inhibitors.

Reference

Bewersdorf J, Carraway H, Prebet T. Emerging treatment options for patients with high-risk myelodysplastic syndrome. Ther Adv Hematol. Published online November 11, 2020. doi:10.1177/2040620720955006

Go here to see the original:
For Patients With HMA-Resistant MDS, What Are Their Options? - AJMC.com Managed Markets Network

Posted in Stem Cell Treatments | Comments Off on For Patients With HMA-Resistant MDS, What Are Their Options? – AJMC.com Managed Markets Network

In COVID-19 Clinical Trials, Experts from Baptist Health’s Cancer Institutes Treat Patients With Mild or Severe Symptoms – Baptist Health South…

Posted: December 22, 2020 at 7:59 am

Offering more hope to patients with COVID-19, cancer experts throughout Baptist Health South Florida are launching new clinical trials. The trials, developed as a result of promising initial emergency and experimental COVID-19 therapies at Miami Cancer Institute on the Baptist Hospital campus in Miami and at the Eugene M. & Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital, span the range of care from the most critically ill to those with mild symptoms.

Guenther Koehne, M.D., Ph.D., director and chief of Stem Cell Transplantation, Hematologic Oncology and Benign Hematology at Miami Cancer Institute.

Its exciting to lead these next-generation clinical trials, said Guenther Koehne, M.D., Ph.D., principal investigator of two of the studies, and director and chief of Stem Cell Transplantation, Hematologic Oncology and Benign Hematology at Miami Cancer Institute. We have learned much about COVID-19 since the pandemic began last winter and our hope is that these trials will lead to tremendous treatment options for patients.

Specialists at both centers are accomplished in many of the techniques and technologies that are doing double-duty as oncology and COVID-19 treatments and pivoted at the start of the pandemic to lead numerous COVID-19 clinical trials.

Trial to Save the Most Critical Patients

Miami Cancer Institute is leading a phase I/IIa clinical trial using mesenchymal stem cells for critically ill patients with COVID-19 induced respiratory failure. Mesenchymal stem cells are derived from umbilical cord lining tissue and aid in healing by regenerating damaged lung tissue. The trial is for hospitalized patients who are receiving oxygen therapy or who are on ventilation support and are not showing improvement.

Early in the pandemic, Miami Cancer Institute treated several patients with mesenchymal stem cells through single-use emergency approval from the U.S. Food and Drug Administration (FDA). The patients, who were among the most ill COVID-19 patients, recovered.

In our early experience with these umbilical cord lining stem cells, we had very promising results, Dr. Koehne said. We are very hopeful that the clinical trial will give us evidence that this treatment can save the lives of those who experience respiratory failure due to COVID-19.

Low-dose Radiation may Reverse Pneumonia

Both Lynn Cancer Institute and Miami Cancer Institute are participating in the PREVENT trial, Low-Dose Radiotherapy for Patients with SARS-COV2 (COVID-19) Pneumonia. With a single, low-dose of thoracic radiation, researchers hope that inflammation in the lungs is reduced and that patients with pneumonia associated with COVID-19 may not need to be placed on a ventilator.

Minesh Mehta, M.D., deputy director and chief of Radiation Oncology at Miami Cancer Institute.

We have seen this treatment option benefit many cancer patients, and the hope is that it also helps those affected by the virus, said Minesh Mehta, M.D., co-principal investigator, deputy director and chief of Radiation Oncology at Miami Cancer Institute.

Patients eligible for the study include hospitalized men and women ages 50 and up who are diagnosed with COVID-19 and pulmonary pneumonia but who are not on ventilators.

This trial gives us the opportunity to administer potentially effective treatment before the need for ICU placement or mechanical ventilation, said Michael Kasper, M.D., co-principal investigator and director of Radiation Oncology at Lynn Cancer Institute.

Radiation therapy has shown a reduction in inflammation in a number of conditions, including viral pneumonia, autoimmune disorders and degenerative joint disorders. At much higher doses, it is also used to treat cancer.

Trial to Shorten Recovery and Reduce Symptoms For Those With Mild Disease

Michael Kasper, M.D., director of Radiation Oncology at Lynn Cancer Institute.

Miami Cancer Institute is also enrolling patients in a phase 2 clinical trial known as BLAZE-4, which continues previous work using a monoclonal antibody, bamlanivimab, to treat patients with milder cases of COVID-19. The Institute participated in the phase 1 study, BLAZE-1, which resulted in Emergency Use Authorization (EUA) status by the FDA.

Bamlanivimab is for patients who are COVID-19 positive but are not hospitalized and have mild symptoms. It must be administered within 72 hours of a positive test result.

The BLAZE-1 study showed a lower subsequent hospitalization rate among those who received the drug versus those who received a placebo, and may reduce the viral load, leading to better outcomes. The BLAZE-4 trial will evaluate the efficacy and safety of bamlanivimab both on its own and in combination with another monoclonal antibody. The drugs work by prohibiting the spread of the virus to additional cells in the body.

We have reached a new level of sophistication trying to treat the virus before it makes you really sick, Dr. Koehne said. Despite the prospect of having COVID-19 vaccines, which are intended to prevent us from getting sick, we need to stay focused on the treatment of those individuals who are symptomatic from the virus.

Tags: COVID-19, Lynn Cancer Institute, Miami Cancer Institute

Original post:
In COVID-19 Clinical Trials, Experts from Baptist Health's Cancer Institutes Treat Patients With Mild or Severe Symptoms - Baptist Health South...

Posted in Stem Cell Treatments | Comments Off on In COVID-19 Clinical Trials, Experts from Baptist Health’s Cancer Institutes Treat Patients With Mild or Severe Symptoms – Baptist Health South…

SPONSORED: 12 Charities of Christmas – Anthony Nolan – The Courier

Posted: December 22, 2020 at 7:59 am

In the run-up to Christmas (between 13th and 24th December) we bring you a different charity that needs your help at this time of year, as part of our dedicated 12 Charities of Christmascampaign

Anthony Nolan saves the lives of people with blood cancer and blood disorders.

For someone with blood cancer, a stem cell transplant could be their last chance of survival. Your support could help it give that person, their family and their friends a second chance of life.

Anthony Nolan is the charity that makes lifesaving connections between people with blood cancer and incredible strangers ready to donate their stem cells. It is saving lives right now. Three lives a day, in fact.

By growing the stem cell register, carrying out ground-breaking research and providing the best post-transplant care, it is giving families a future. But it cant do it without you. Without you, there is no cure.

Anthony Nolans vision: To save and improve the lives of everyone who needs a stem cell transplant.

This is a fundamental vision and, if youve known the charity a while, youll notice it hasnt changed. Thats because its cause is as relevant now as it was 45 years ago when Shirley Nolan first started the charity to find a matching stem cell donor for her son, Anthony.

Its aims:

1. Together, we can provide outstanding services to patients and the clinical community

2. Together, we can drive lifesaving research and turn it into action for patients

3. Together, we can harness the collective power of our supporters to champion and enable our lifesaving work

4. Together, we can be a stronger voice for patients to ensure they receive the best possible care

5. Together, we can

Anthony Nolans 2019-2022 Organisational Strategy

In April 2019, it launched our new strategy, Together, we can save lives. This strategy sets out what it wants to achieve in these three years and beyond, as it leads the way into a future of new treatments and new ways of working. For more information or to donate, click here.

This feature is brought to you as part of our 12 Charities of Christmas campaign and has been sponsored by:

William Wallace has been self-employed for 54 years, starting with Braefoot Garage in Methil, with his junior John Stewart, who he is still in contact with today.

Aberhill Metals was created in 1986 and has grown, with his sons Derek and William Jnr joining him, from leaving school. He has always had the loyal and supportive help of his wife Margo, of 58 years, who has endured the pressures of running a business, and his extended family of 5, grandchildren of 16 and great grandchildren of 5

The company is well known throughout North East Fife for Skip Hire.

During the last year with the Covid lockdown, it kept working supplying skips. Even after a major fire at its premises, Aberhill didnt stop. Still up and running with the support of all staff.

Go here to read the rest:
SPONSORED: 12 Charities of Christmas - Anthony Nolan - The Courier

Posted in Stem Cell Treatments | Comments Off on SPONSORED: 12 Charities of Christmas – Anthony Nolan – The Courier

Page 796«..1020..795796797798..810820..»